Jens T. Siveke

Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial

Andrea Wang‐Gillam, Chung‐Pin Li, G. Bodoky et al. · The Lancet · 2015 · 1.2K citations

Medicine, Oncology, Pharmacology +16

EGF Receptor Is Required for KRAS-Induced Pancreatic Tumorigenesis

Christine Ardito-Abraham, Barbara M. Grüner, Kenneth K. Takeuchi et al. · Cancer Cell · 2012 · 526 citations

Medicine, Molecular Biology, Oncology +14

Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer

Joseph Tintelnot, Yang Xu, Till Robin Lesker et al. · Nature · 2023 · 452 citations · Full text

Medicine, Cancer Biology, Oncology +17

Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma

Paweł K. Mazur, Alexander Herner, Stephano S. Mello et al. · Nature Medicine · 2015 · 417 citations · Full text

Medicine, Molecular Biology, Oncology +17

NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors

Andrea Wang‐Gillam, Richard Hubner, Jens T. Siveke et al. · European Journal of Cancer · 2019 · 328 citations · Full text

Medicine, Oncology, Pharmacology +17